Indogulf Cropsciences Limited IPO: 10 Key Things to Know Before Investing

Indogulf Cropsciences Limited is involved in the manufacturing of crop protection products, plant nutrients, and biologicals-critical components for improving farm productivity. Their portfolio includes advanced formulations like WDG, SC, ULV, and EW in multiple forms such as powders, granules, and liquids.

The company’s R&D-driven approach and international presence across 34 countries make it a strong player in the agrochemical sector. They’ve been recognized by the Government of India as a Two-Star Export House, and their product line has grown from 198 in FY22 to 259 in FY24. With a wide distribution network and increasing innovation capabilities, Indogulf positions itself well in the growing agricultural input space. 

Here are the key details of the IPO:

• IPO dates: June 26th - 30th, 2025

• Listing date: July 3rd, 2025

• Price band: ₹105 - ₹111 per share

• Total issue size: ₹200 Cr

• Face value: ₹10 per share

• Listing Exchange: BSE, NSE

• Lot Size: 135 Shares

• Promoters: Om Prakash Aggarwal, Sanjay Aggarwal, Anshu Aggarwal, and Arnav Aggarwal 

The minimum investment required to apply for the Indogulf Cropsciences IPO is ₹14,175, based on the lot size of 135 shares at the lower price band of ₹105 per share. To enhance the chances of allotment, investors can consider applying at the upper price band, which would require ₹14,985 (135 shares at ₹111 per share). 

Established as a key player in Indian agriculture, Indogulf Cropsciences manufactures a wide range of agri-inputs:

• Product Portfolio: Crop protection products, plant nutrients, and biologicals using advanced formulations.

• Exports: Operations span over 34 countries across various continents.

• Associated Company: M & B Engineering, which manufactures key technical ingredients like Spiromesifen.

Their focus lies in addressing productivity challenges in agriculture with a research-driven product range and a robust distribution ecosystem covering 22 Indian states, 3 UTs, and a global partner network. 

The primary objectives of the Indogulf Cropsciences IPO are:

• To fund working capital requirements.

• To repay or prepay outstanding borrowings in part or full.

• To invest in capital expenditure for setting up a dry flowable (DF) plant in Sonipat, Haryana. 

Although the exact breakup has not been disclosed, the IPO allocation is typically structured as follows:

• QIB Shares Offered: Not less than 50% of the Issue

• Retail Shares Offered: Not more than 35% of the Issue

• NII (HNI) Shares Offered: Not more than 15% of the Issue 

Strengths:

• Broad product portfolio across crop protection, nutrients, and biologicals

• Widespread domestic and international market presence

• Consistent product innovation backed by NABL-accredited R&D

• Large distribution network including 5,772 domestic distributors and 169 institutional partners

Risks:

• Rising input costs or supply disruptions can affect margins

• Seasonal and climatic conditions impact business performance

• Regulatory changes in export markets could limit international growth

• Global uncertainties (pandemics, natural disasters) could affect operations 

The company has shown consistent performance over recent years (INR Cr): 

The financials show stability and modest growth in revenue and profit, with a gradual increase in asset base-indicating healthy business expansion. 

• Basis of allotment: July 1, 2025

• Refund initiation: July 2, 2025

• Shares credited to demat accounts: July 2, 2025

• Listing date: July 3, 2025 

Indogulf Cropsciences offers a strong investment proposition in India’s growing agri-input market. With a wide product portfolio, strong R&D backing, and a global presence, the company is well-positioned to capture future growth. That said, it operates in a seasonally sensitive and input-dependent industry, which can affect margins.

As always, evaluate your investment goals and risk profile before applying for the IPO.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult your financial advisor before investing.